dataesr/scientific-paragraphs-categorization huggingface dataset:
Other measures Sociodemographic information. Including gender, age, marital status, familial situation at home (alone, spouse, child, etc), academic level, and socioeconomic status are collected or during the first interview either from the medical records. Medical condition and treatment. Data about the medical condition of the participants including previous and present affections  (somatic, neurologic, psychiatric) , family history neurological affections, medical treatment at hospital entrance, vascular risk factors (BMI, diabetes, cholesterol, high blood pressure, alcohol and other substance use). Stroke characteristics and functional deficit. Stroke localization (right or left hemisphere) and type (ischemic or hemorrhagic) based on medical imageries and exams conclusions. In case of ischemic stroke, we record if patients have received a thrombolytic treatment.
Data Analysis Outcomes and statistical methods for primary objectives Feasibility and acceptability of the EMA method will be assessed by examination of acceptance and compliance rate, fatigue effects and reactivity to assessment: completion rate during each week, participation at follow-up weeks (phases 2 and 3), missing data and assessment duration across time during each phase. Descriptive analysis will be performed to describe feasibility and acceptability. Compliance will be assessed as the completion rate of EMA questionnaires. This rate will be calculated as the ratio of completed questionnaires to all sent questionnaires within each phase (four questionnaires per day during 7 days for each participant). Follow-up participation will be the ratio of number of participants at phase 2 and 3 to the number of participants at inclusion (phase 1).
ETHICS STATEMENT This study is carried out in accordance with the Comité de Protection des Personnes Ile-De-France II (CPP IDF II). All participants give their informed consent in accordance of the Declaration of Helsinki. As we mentioned earlier, a particular concern is given to patients' safety. Participants will be informed and advised to share concerns with care professionals and their relatives whether they feel distress. Research staff will systematically contact participants eliciting psychological distress or suicidal ideation and direct them toward mental or medical care providers considering the participant's needs. Participants will be instructed to answer prompts on the application only when it is safe and convenient. This protocol has already received ethical approval by the Comité de Protection des Personnes Ile-De-France II (CPP IDF II) and has been recorded on the European Clinical Trials Database (EudraCT Number/ID RCB 2014-A01937-40).
BACKGROUND Breast cancer is common with 1 in 8 women affected in their lifetime{ADDIN CSL_CITATION { "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "URL" : "http://www. cancerresearchuk. org/health-professional/cancer-statistics/risk/lifetimerisk#ref-2", "accessed" : { "date-parts" :  [ [ "2017", "4", "20" ]  ] }, "author" : [ { "droppingparticle" : "", "family" : "Cancer Research UK", "given" : "", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" } ], "id" : "ITEM-1", "issued" : { "date-parts" : [ [ "0" ] ] }, "title" : "Lifetime risk of cancer", "type" : "webpage" }, "uris" : [ "http://www. mendeley. com/documents/?uuid=aed5359d-b675-4692-bce0-e4d149e425f0" ] } ], "mendeley" : { "formattedCitation" : "<sup>1</sup>", "plainTextFormattedCitation" : "1", "previouslyFormattedCitation" : "<sup>1</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github.
mendeley. com/documents/?uuid=c081ca67-73f8-445f-89cc-992271a62a1b" ] } ], "mendeley" : { "formattedCitation" : "<sup>2,3</sup>", "plainTextFormattedCitation" : "2,3", "previouslyFormattedCitation" : "<sup>2,3</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github. com/citation-style-language/schema/raw/master/cslcitation. json" }}, the demonstration of the superiority of aromatase inhibitors over tamoxifen {ADDIN CSL_CITATION { "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "DOI" : "10. 1016/S1470-2045(10)70257-6", "ISBN" : "1474-5488 (Electronic)\\r1470-2045 (Linking)", "ISSN" : "14702045", "PMID" : "21087898", "abstract" : "Background: The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer.
In this analysis, we assess the long-term outcomes after a median follow-up of 120 months. Methods: We used a proportional hazards model to assess the primary endpoint of disease-free survival, and the secondary endpoints of time to recurrence, time to distant recurrence, incidence of new contralateral breast cancer, overall survival, and death with or without recurrence in all randomised patients (anastrozole n=3125, tamoxifen n=3116) and hormone-receptor-positive patients (anastrozole n=2618, tamoxifen n=2598). After treatment completion, we continued to collect data on fractures and serious adverse events in a masked fashion (safety population: anastrozole n=3092, tamoxifen n=3094). This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN18233230.
e. , initial adjuvant aromatase inhibitor therapy or sequential adjuvant aromatase inhibitor therapy). \u00a9 2007 Future Drugs Ltd. ", "author" : [ { "droppingparticle" : "", "family" : "Monnier", "given" : "A M", "non-dropping-particle" : "", "parsenames" : false, "suffix" : "" } ], "container-title" : "Expert Review of Anticancer Therapy", "id" : "ITEM-2", "issue" : "5", "issued" : { "date-parts" :  [ [ "2007" ]  ] }, "page" : "627-634", "title" : "The breast international group 1-98 trial: Big results for women with hormone-sensitive early breast cancer", "type" : "article-journal", "volume" : "7" }, "uris" : [ "http://www. mendeley. com/documents/?uuid=92db92c7-c28f-46f9-b6af-8ba86b461074" ] } ], "mendeley" : { "formattedCitation" : "<sup>4,5</sup>", "plainTextFormattedCitation" : "4,5", "previouslyFormattedCitation" : "<sup>4,5</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github.
Methods The HERA trial is an international, multicentre, randomised, open-label, phase 3 trial comparing treatment with trastuzumab for 1 and 2 years with observation after standard neoadjuvant chemotherapy, adjuvant chemotherapy, or both in 5102 patients with HER2-positive early breast cancer. The primary endpoint was disease-free survival. The comparison of 2 years versus 1 year of trastuzumab treatment involved a landmark analysis of 3105 patients who were diseasefree 12 months after randomisation to one of the trastuzumab groups, and was planned after observing at least 725 disease-free survival events. The updated intention-to-treat comparison of 1 year trastuzumab treatment versus observation alone in 3399 patients at a median follow-up of 8 years (range 0-10) is also reported. This study is registered with ClinicalTrials.
gov, number NCT00045032. Findings We recorded 367 events of disease-free survival in 1552 patients in the 1 year group and 367 events in 1553 patients in the 2 year group (hazard ratio [HR] 0??99, 95% CI 0??85-1??14, p=0??86). Grade 3-4 adverse events and decreases in left ventricular ejection fraction during treatment were reported more frequently in the 2 year treatment group than in the 1 year group  (342 [20??4%]  vs 275 [16??3%] grade 3-4 adverse events, and 120 [7??2%] vs 69 [4??1%] decreases in left ventricular ejection fraction, respectively). HRs for a comparison of 1 year of trastuzumab treatment versus observation were 0??76 (95% CI 0??67-0??86, p<0??0001) for disease-free survival and 0??76 (0??65-0??88, p=0??0005) for overall survival, despite crossover of 884 (52%) patients from the observation group to trastuzumab therapy.
mendeley. com/documents/?uuid=13b1240b-54c1-44f2-8a79-07e578eda08e" ] } ], "mendeley" : { "formattedCitation" : "<sup>6\u20138</sup>", "plainTextFormattedCitation" : "6\u20138", "previouslyFormattedCitation" : "<sup>6\u20138</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github. com/citation-style-language/schema/raw/master/csl-citation. json" }}, taxane based chemotherapy{ADDIN CSL_CITATION { "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "DOI" : "10. 1016/j. breastdis. 2013. 01. 026", "ISBN" : "0140-6736", "ISSN" : "1043321X", "PMID" : "22152853", "abstract" : "Background: Moderate differences in efficacy between adjuvant chemotherapy regimens for breast cancer are plausible, and could affect treatment choices. We sought any such differences. Methods: We undertook individual-patient-data meta-analyses of the randomised trials comparing: any taxane-plusanthracycline-based regimen versus the same, or more, non-taxane chemotherapy (n=44 000); one anthracycline-based regimen versus another (n=7000) or versus cyclophosphamide, methotrexate, and fluorouracil (CMF; n=18 000); and polychemotherapy versus no chemotherapy (n=32 000).
mendeley. com/documents/?uuid=389b2c56-d46d-477a-8e94-013b128aaf4d" ] } ], "mendeley" : { "formattedCitation" : "<sup>9,10</sup>", "plainTextFormattedCitation" : "9,10", "previouslyFormattedCitation" : "<sup>9,10</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github. com/citation-style-language/schema/raw/master/cslcitation. json" }} and bisphosphonate treatment{ADDIN CSL_CITATION { "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "DOI" : "10. 1016/S0140-6736(15)60908-4", "ISBN" : "1474-547X (Electronic)\\r0140-6736 (Linking)", "ISSN" : "01406736", "PMID" : "26211824", "abstract" : "Background Bisphosphonates have profound eff ects on bone physiology, and could modify the process of metastasis. We undertook collaborative meta-analyses to clarify the risks and benefi ts of adjuvant bisphosphonate treatment in breast cancer.
", "author" : [ { "dropping-particle" : "", "family" : "Breast Cancer Trialists", "given" : "Early", "nondropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" : "Group", "given" : "Collaborative", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" } ], "container-title" : "The Lancet", "id" : "ITEM-1", "issue" : "15", "issued" : { "date-parts" : [ [ "2015" ] ] }, "page" : "1-9", "title" : "Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials", "type" : "article-journal", "volume" : "6736" }, "uris" : [ "http://www. mendeley. com/documents/?uuid=5b5a5a75-4fed-4074-87b1-55e8c3edf41d" ] } ], "mendeley" : { "formattedCitation" : "<sup>11</sup>", "plainTextFormattedCitation" : "11", "previouslyFormattedCitation" : "<sup>11</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github.
METHODS: The most recent published results and, where available, updated patient-level data from randomized controlled trials of BCT and mastectomy for early-stage breast cancer were combined in a meta-analysis using a random effects model. Pooled survival rates and odds ratios were generated according to subgroups of nodal status and tumor size. Five-and 10-year odds ratios were also determined according to adjuvant radiation protocol. RESULTS: The pooled odds ratio comparing 10-year survival for BCT and mastectomy was 0. 91. The odds ratios comparing the two treatment regimens were not significant after grouping according to tumor size and nodal status. When more than 50% of node-positive patients in both the mastectomy and BCT arms received adjuvant radiation, both arms had similar survival rates.
The risk of local recurrence was lower during the first 5 years for the breast-conserving surgery group as compared with the mastectomy group, but higher after 5 years (P = 10(-4) for a different treatment effect over time). Similar results were found in a database including 1847 patients with small breast tumours at diagnosis. In this analysis, late breast recurrences were also more frequent in the breast-conserving surgery group and this treatment effect was greater among younger patients (</=40 years at the time of diagnosis). CONCLUSIONS: Late breast recurrences were more frequently observed in younger patients treated with breast-conserving treatment compared with those submitted to mastectomy. These results require confirmation in other randomised studies so that younger patients with early breast cancer can receive adequate counselling and so that a more stringent long-term follow-up policy can be adopted when breastconserving treatment is planned.
1056/NEJMoa020128", "ISBN" : "1533-4406 (Electronic)\\r0028-4793 (Linking)", "ISSN" : "1533-4406", "PMID" : "12192016", "abstract" : "BACKGROUND: In 1976, we initiated a randomized trial to determine whether lumpectomy with or without radiation therapy was as effective as total mastectomy for the treatment of invasive breast cancer. METHODS: A total of 1851 women for whom follow-up data were available and nodal status was known underwent randomly assigned treatment consisting of total mastectomy, lumpectomy alone, or lumpectomy and breast irradiation. Kaplan-Meier and cumulative-incidence estimates of the outcome were obtained. RESULTS: The cumulative incidence of recurrent tumor in the ipsilateral breast was 14. 3 percent in the women who underwent lumpectomy and breast irradiation, as compared with 39.
", "type" : "articlejournal", "volume" : "347" }, "uris" : [ "http://www. mendeley. com/documents/?uuid=2411ba6b-9560-48ac-8235-bb3b4011e58f" ] } ], "mendeley" : { "formattedCitation" : "<sup>12\u201318</sup>", "plainTextFormattedCitation" : "12\u201318", "previouslyFormattedCitation" : "<sup>12\u201318</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github. com/citation-style-language/schema/raw/master/csl-citation. json" }}. Breast conservation offers a number of advantages over mastectomy. Preservation of the breast has psychological benefits, helping patients cope with their diagnosis and treatment{ADDIN CSL_CITATION { "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "DOI" : "10. 1111/j. 1075-122X. 2004. 21323. x", "ISSN" : "1075-122X", "PMID" : "15125749", "abstract" : "\u1b7f Abstract: There are many conflicting results in the literature comparing worse for younger patients.
", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "droppingparticle" : "", "family" : "Blamey", "given" : "R. W. ", "non-dropping-particle" : "", "parsenames" : false, "suffix" : "" } ], "container-title" : "European Journal of Cancer", "id" : "ITEM-2", "issue" : "15", "issued" : { "date-parts" : [ [ "2000" ] ] }, "page" : "1938-1943", "title" : "Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction", "type" : "article-journal", "volume" : "36" }, "uris" : [ "http://www. mendeley. com/documents/?uuid=4e396e8a-869c-447b-b01b-44b9c94acaef" ] } ], "mendeley" : { "formattedCitation" : "<sup>19,20</sup>", "plainTextFormattedCitation" : "19,20", "previouslyFormattedCitation" : "<sup>19,20</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github.
mendeley. com/documents/?uuid=1f96703b-acb2-4054-8997-b6199f562954" ] } ], "mendeley" : { "formattedCitation" : "<sup>21,22</sup>", "plainTextFormattedCitation" : "21,22", "previouslyFormattedCitation" : "<sup>21,22</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github. com/citation-stylelanguage/schema/raw/master/csl-citation. json" }}). In the UK, day case wide local excision is supported by best practice tariffs. Shorter recovery with earlier return to work, particularly when compared to mastectomy with immediate reconstruction, has economic benefits for patients. For the majority of patients in whom wide local excision is technically and oncologically feasible, the cosmetic outcome is superior to what can be achieved by mastectomy and reconstruction{ADDIN CSL_CITATION { "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "DOI" : "10.
mendeley. com/documents/?uuid=e02c0541-f2ce-4d5c-84a8-d51e1dede2a3" ] } ], "mendeley" : { "formattedCitation" : "<sup>19</sup>", "plainTextFormattedCitation" : "19", "previouslyFormattedCitation" : "<sup>19</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github. com/citation-style-language/schema/raw/master/cslcitation. json" }}. Local control in BCT is largely attributed to 3 factors: clear resection margins, adjuvant radiotherapy and systemic therapy. Radiotherapy to the remaining breast has been shown to reduce local recurrence by 19%{ADDIN CSL_CITATION { "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "DOI" : "10. 1016/S0140-6736(05)67887-7", "ISBN" : "0140-6736", "ISSN" : "01406736", "PMID" : "16360786", "abstract" : "Background: In early breast cancer, variations in local treatment that substantially affect the risk of locoregional recurrence could also affect long-term breast cancer mortality.
", "nondropping-particle" : "", "parse-names" : false, "suffix" : "" } ], "container-title" : "Lancet", "id" : "ITEM-1", "issue" : "9503", "issued" : { "date-parts" : [ [ "2005" ] ] }, "page" : "2087-2106", "title" : "Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials", "type" : "article", "volume" : "366" }, "uris" : [ "http://www. mendeley. com/documents/?uuid=7ab17849-3114-4d25-b707-7498fd8bdd02" ] } ], "mendeley" : { "formattedCitation" : "<sup>23</sup>", "plainTextFormattedCitation" : "23", "previouslyFormattedCitation" : "<sup>23</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github. com/citation-style-language/schema/raw/master/cslcitation. json" }} and systemic therapy in the form of endocrine treatment and chemotherapy have been shown to reduce local recurrence by approximately 10%{ADDIN CSL_CITATION { "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "DOI" : "10.
", "type" : "article-journal", "volume" : "88" }, "uris" : [ "http://www. mendeley. com/documents/?uuid=131ce9dc-6c93-472d-b26f-19bcd64cd6cc" ] } ], "mendeley" : { "formattedCitation" : "<sup>24,25</sup>", "plainTextFormattedCitation" : "24,25", "previouslyFormattedCitation" : "<sup>24,25</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github. com/citation-stylelanguage/schema/raw/master/csl-citation. json" }}. A recent meta-analysis on surgical margins and local recurrence demonstrated a median local recurrence rate after BCT of 5. 3% in 28,162 women undergoing BCT{ADDIN CSL_CITATION { "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "DOI" : "10. 1245/s10434-014-3480-5", "ISBN" : "1068-9265", "ISSN" : "1068-9265", "PMID" : "24473640", "abstract" : "Purpose: There is no consensus on what constitutes adequate negative margins in breast-conserving therapy (BCT).
mendeley. com/documents/?uuid=db62836c-3d64-49df-8f72-aa33c7d56cff" ] } ], "mendeley" : { "formattedCitation" : "<sup>26</sup>", "plainTextFormattedCitation" : "26", "previouslyFormattedCitation" : "<sup>26</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github. com/citation-style-language/schema/raw/master/cslcitation. json" }}. This study found that local recurrence is more than twice as likely with positive margins compared to negative margins (odds ratio 2. 44). However, as long as there was no ink on tumour, wider margins did not significantly alter the local recurrence rate. Importantly, this finding was also true in unfavourable cases such as in younger patients, those with more aggressive tumour biology, lobular cancers or those with an extensive intraductal component.
L. ", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" : "Morrow", "given" : "Monica", "nondropping-particle" : "", "parse-names" : false, "suffix" : "" } ], "container-title" : "Ann Surg Oncol", "id" : "ITEM-1", "issue" : "3", "issued" : { "date-parts" : [ [ "2014" ] ] }, "page" : "704-16", "title" : "Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer", "type" : "article-journal", "volume" : "21" }, "uris" : [ "http://www. mendeley. com/documents/?uuid=0817464e-9ebe-49d4-839b- 43d3775fc775" ] } ], "mendeley" : { "formattedCitation" : "<sup>27</sup>", "plainTextFormattedCitation" : "27", "previouslyFormattedCitation" : "<sup>27</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github.
com/documents/?uuid=43d5ea73-d7b1-4bc1-a5ee-d8c5a562a580" ] } ], "mendeley" : { "formattedCitation" : "<sup>28</sup>", "plainTextFormattedCitation" : "28", "previouslyFormattedCitation" : "<sup>28</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github. com/citation-style-language/schema/raw/master/cslcitation. json" }}. In 2016, SSO-ASTRO-ASCO published a meta-analysis on margin width and local recurrence in DCIS, resulting in its consensus guideline of 2mm for DCIS{ADDIN CSL_CITATION { "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "DOI" : "10. 1016/j. prro. 2016. 06. 011", "ISBN" : "1879-355X (Electronic)\\r0360-3016 (Linking)", "ISSN" : "18798500", "PMID" : "27528719", "abstract" : "Purpose Controversy exists regarding the optimal negative margin width for ductal carcinoma in situ (DCIS) treated with breast-conserving surgery and whole-breast irradiation.
", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" } ], "container-title" : "Practical Radiation Oncology", "id" : "ITEM-1", "issue" : "5", "issued" : { "date-parts" : [ [ "2016" ] ] }, "page" : "287-295", "title" : "Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ", "type" : "article-journal", "volume" : "6" }, "uris" : [ "http://www. mendeley. com/documents/?uuid=02ae3e81-a1cc-448c-b91b-22a45d296afe" ] } ], "mendeley" : { "formattedCitation" : "<sup>29</sup>", "plainTextFormattedCitation" : "29", "previouslyFormattedCitation" : "<sup>29</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github.
com/citation-style-language/schema/raw/master/cslcitation. json" }}. Despite an increasing body of evidence supporting narrow margins in BCT, there is still a lack of consensus in margin policy in the UK. In addition to the international guidelines published recently, national and regional guidelines are also available and include guidance from the National Institute for Health and Care Excellence (NICE) which defines a margin clearance of 2mm for DCIS{ADDIN CSL_CITATION { "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "id" : "ITEM-1", "issued" : { "date-parts" : [ [ "2009" ] ] }, "title" : "Early and locally advanced breast cancer: diagnosis and treatment. NICE guideline (CG80). ", "type" : "report" }, "uris" : [ "http://www. mendeley. com/documents/?uuid=13a1305c-081f-4ac5-86d4-d8fcdee015f5" ] } ], "mendeley" : { "formattedCitation" : "<sup>30</sup>", "plainTextFormattedCitation" : "30", "previouslyFormattedCitation" : "<sup>30</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github.
", "type" : "article-journal", "volume" : "22" }, "uris" : [ "http://www. mendeley. com/documents/?uuid=c0ceb51e-2fd6-4d1a-8487-76ada0a9ad46" ] } ], "mendeley" : { "formattedCitation" : "<sup>31</sup>", "plainTextFormattedCitation" : "31", "previouslyFormattedCitation" : "<sup>31</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "https://github. com/citation-stylelanguage/schema/raw/master/csl-citation. json" }}, increased scarring and further general anaesthetic. A larger retrospective study of BCT in England using hospital episode statistics found an overall re-operation rate of 20% with substantial differences in the rates between NHS Trusts (10th and 90th centiles of 12. 2% and 30. 2%){ADDIN CSL_CITATION { "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "DOI" : "10. 1136/bmj.